Celsion Corp. (CLSN) Shares Skyrocket After Publication of Phase 1 Study of ThermoDox and Ultrasound


 
 
10:04 11/21/2017

An oncology company focusing on development of products for the treatment of cancer, Celsion Corporation CLSN , announced the publication for the clinical trial for TARDOX.

This is a phase 1 study to determine the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox) using ultrasound in patients currently experiencing live tumors. The purpose of the study was intended to establish the safety and feasibility of the drug ThermoDox and how it was affected in solid live tumors.

The main outcome of the clinical trial was the exact dosage needed of doxorubicin before and after focused ultrasound (FUS). The second outcome recorded was the safety of the patient during and after the controlled FUS-mediated hyperthermia was treated.

The National Institute for Health Research (NIHR) Oxford Biomedical Research supported the TARDOX Study which was carried out as a multi-disciplinary collaboration between Celsion CLSN  and Oxford University.

Celsion also announced they will be presenting the results of phase 1 at the Radiological Society of North America (RSNA) 2017 Annual Meeting next week at the McCormick Center in Chicago, IL.

Celsion’s chairman, president and CEO, Michael H. Tardugno commented, “Both Celsion and Oxford believe there is significant potential when combining ThermoDox with focused ultrasound to treat a broad range of malignancies, including primary live cancer.”

“TARDOX, the ThermoDox/Focused Ultrasound trial, is an important step in demonstrating that ultrasound-induced hyperthermia can enable the highly targeted delivery of chemotherapeutic agents to tumors non-invasively,” Tardugno added.

This morning, shares of Celsion CLSN  opened 75% up from yesterday’s close and ran a little more to $3.96 a share. Analysts are predicting shares could even move higher if the presentation next week goes well for them.


This article has been provided by a Chasing Markets contributor. All content submitted by this author represent their personal opinions, and should be considered as such for entertainment purpose only. All opinions expressed are those of the writer, and may not necessarily represent fact, opinions, or bias of Chasing Markets.
Most Read